Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119316 | 0.89 | ROCK2 (0.43) | ROCK2ROCK1ENPP2AURKASRC | |
| SCHEMBL353551 | 0.87 | ROCK2 (0.44) | ROCK2ROCK1ENPP2AURKASRC | |
| SCHEMBL352905 | 0.82 | ROCK2 (0.47) | ROCK2ROCK1SRCATG4B | |
| SCHEMBL19119399 | 0.81 | ROCK2 (0.43) | ROCK2ROCK1ENPP2AURKASRC | |
| SCHEMBL354322 | 0.79 | ROCK2 (0.45) | ROCK2ROCK1AURKARPS6KB1SRC | |
| SCHEMBL352137 | 0.79 | ROCK2 (0.45) | ROCK2ROCK1SRCATG4B | |
| SCHEMBL353532 | 0.79 | ROCK2 (0.54) | ROCK2ROCK1ATG4BEPHX2 | |
| SCHEMBL353537 | 0.78 | ROCK1 (0.51) | ROCK2ROCK1ATG4BEPHX2 | |
| SCHEMBL354366 | 0.78 | ROCK2 (0.51) | ROCK2ROCK1ATG4B | |
| SCHEMBL354410 | 0.78 | ROCK1 (0.51) | ROCK2ROCK1ATG4BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ROCK2 4626/4885ROCK1 4747/4885ENPP2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.